These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 34782799)

  • 21. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
    Celik I; Erol M; Duzgun Z
    Mol Divers; 2022 Feb; 26(1):279-292. PubMed ID: 33765239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
    Taha HR; Keewan N; Slati F; Al-Sawalha NA
    Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
    Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
    Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of remdesivir for patients with Covid-19: a review article.
    Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
    Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
    SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods.
    Hoseininezhad-Namin MS; Rahimpour E; Jouyban A
    Drug Metab Rev; 2024; 56(2):127-144. PubMed ID: 38445647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Dong L; Hu S; Gao J
    Drug Discov Ther; 2020; 14(1):58-60. PubMed ID: 32147628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.
    Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL
    PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
    Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
    SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.